Success Story

Interius Biotherapeutics signs multiple commercial agreements with Penn to develop an exciting new cell and gene therapy delivery platform

Interius Biotherapeutics seeks to eliminate the ex vivo manufacturing step required for many cell and gene therapies through direct viral delivery of genes to immune and blood cells inside patients themselves. Potential applications include treatments for a variety of blood disorders, as well as the delivery of chimeric antigen receptors to cytotoxic T-cells to attack various forms of cancer or into regulatory T-cells to address certain types of autoimmune disease. If successful, this new platform technology and approach may lead to significantly more affordable and more accessible cell and gene therapies.

Interius was spun-out of Penn by Saar Gill, M.D., Ph.D., Scientific co-director, Transplant & Cell Therapy program at The University of Pennsylvania, and a prominent inventor in the CAR-T field and Bruce Peacock, an experienced biotechnology executive and successful entrepreneur.

Screenshot: Latest Penn biotech spinout taking on cancer raises $1.6M from investors (Philadelphia Business Journal)

Skip to content